Oncternal Therapeutics Inc
NASDAQ:ONCT

Watchlist Manager
Oncternal Therapeutics Inc Logo
Oncternal Therapeutics Inc
NASDAQ:ONCT
Watchlist
Price: 0.5266 USD Market Closed
Market Cap: 1.6m USD

ONCT's latest stock split occurred on Jan 8, 2024

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, ONCT traded at 0.34 per share. Afterward, the share price was about 7.2.

The adjusted shares began trading on Jan 8, 2024. This was ONCT's 3rd stock split, following the previous one in Jun 10, 2019.

Last Splits:
Jan 8, 2024
1-for-20
Jun 10, 2019
1-for-7
Dec 6, 2016
1-for-10
Pre-Split Price
6.8 0.34
Post-Split Price
7.2
Before
After
Last Splits:
Jan 8, 2024
1-for-20
Jun 10, 2019
1-for-7
Dec 6, 2016
1-for-10

Oncternal Therapeutics Inc
Stock Splits History

ONCT Stock Splits Timeline
Jan 8, 2024
Jan 8, 2024
Split 1-for-20
/0.05
Pre-Split Price
6.8 0.34
Post-Split Price
7.2
Before
After
Jun 10, 2019
Jun 10, 2019
Split 1-for-7
/0.14285714285714
Pre-Split Price
168 1.2
Post-Split Price
143
Before
After
Dec 6, 2016
Dec 6, 2016
Split 1-for-10
/0.1
Pre-Split Price
938 0.67
Post-Split Price
956.2
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Oncternal Therapeutics Inc
Glance View

Market Cap
1.6m USD
Industry
Biotechnology

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 26 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

ONCT Intrinsic Value
4.9239 USD
Undervaluation 89%
Intrinsic Value
Price
Back to Top